277 related articles for article (PubMed ID: 30348619)
41. 5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations.
Teperikidis E; Boulmpou A; Charalampidis P; Tsavousoglou C; Giannakoulas G; Papadopoulos CE; Vassilikos V
Acta Cardiol; 2022 Feb; 77(1):1-13. PubMed ID: 33683181
[TBL] [Abstract][Full Text] [Related]
42. ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.
Ryu MH; Kang YK
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1745-51. PubMed ID: 19954285
[TBL] [Abstract][Full Text] [Related]
43. Symptomatic cardiotoxicity associated with 5-fluorouracil.
Meyer CC; Calis KA; Burke LB; Walawander CA; Grasela TH
Pharmacotherapy; 1997; 17(4):729-36. PubMed ID: 9250550
[TBL] [Abstract][Full Text] [Related]
44. Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort.
Mulrooney DA; Hyun G; Ness KK; Ehrhardt MJ; Yasui Y; Duprez D; Howell RM; Leisenring WM; Constine LS; Tonorezos E; Gibson TM; Robison LL; Oeffinger KC; Hudson MM; Armstrong GT
BMJ; 2020 Jan; 368():l6794. PubMed ID: 31941657
[TBL] [Abstract][Full Text] [Related]
45. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
[TBL] [Abstract][Full Text] [Related]
46. Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity.
Le Brun-Ly V; Martin J; Venat-Bouvet L; Darodes N; Labourey JL; Genet D; Tubiana-Mathieu N
Oncology; 2009; 76(5):322-5. PubMed ID: 19307737
[TBL] [Abstract][Full Text] [Related]
47. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
[TBL] [Abstract][Full Text] [Related]
48. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN).
Pituskin E; Haykowsky M; McNeely M; Mackey J; Chua N; Paterson I
BMC Cancer; 2016 Sep; 16(1):733. PubMed ID: 27629548
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of oral administration of cystine and theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery: study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial.
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Ariyoshi K; Oyamada S; Iwase S
BMJ Open; 2018 Jul; 8(7):e021442. PubMed ID: 30030317
[TBL] [Abstract][Full Text] [Related]
50. Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis.
Zhu L; Liu J; Ma S
Pathol Oncol Res; 2016 Oct; 22(4):853-61. PubMed ID: 27236591
[TBL] [Abstract][Full Text] [Related]
51. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
52. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.
Polk A; Vaage-Nilsen M; Vistisen K; Nielsen DL
Cancer Treat Rev; 2013 Dec; 39(8):974-84. PubMed ID: 23582737
[TBL] [Abstract][Full Text] [Related]
53. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
54. [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Jensen SA; Baeksgaard L; Petersen LN; Reiter L; Sørensen JB
Ugeskr Laeger; 2010 Jan; 172(1):48-51. PubMed ID: 20056096
[TBL] [Abstract][Full Text] [Related]
55. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Cassidy J; Twelves C; Van Cutsem E; Hoff P; Bajetta E; Boyer M; Bugat R; Burger U; Garin A; Graeven U; McKendric J; Maroun J; Marshall J; Osterwalder B; Pérez-Manga G; Rosso R; Rougier P; Schilsky RL;
Ann Oncol; 2002 Apr; 13(4):566-75. PubMed ID: 12056707
[TBL] [Abstract][Full Text] [Related]
56. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Hurwitz H; Kabbinavar F
Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
[TBL] [Abstract][Full Text] [Related]
57. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
58. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Twelves CJ
Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
[TBL] [Abstract][Full Text] [Related]
59. Colorectal cancer: chemotherapy treatment overview.
Royce ME; Medgyesy D; Zukowski TH; Dwivedy S; Hoff PM; Pazdur R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):40-6. PubMed ID: 11200148
[TBL] [Abstract][Full Text] [Related]
60. The Role of Vasospasm and Microcirculatory Dysfunction in Fluoropyrimidine-Induced Ischemic Heart Disease.
Fabin N; Bergami M; Cenko E; Bugiardini R; Manfrini O
J Clin Med; 2022 Feb; 11(5):. PubMed ID: 35268333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]